Analytical Data
-
Gene name
HLA-A*02:01&B2M&HIV Gag(SLYNTVATL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & HIV Gag (SLYNTVATL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&SLYNTVATL
-
Molecular Weight
40-43 kDa and 14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01-B2M-HIV Gag (SLYNTVATL) monomer recombinant protein is a significant focus in immunological research due to its potential applications in HIV vaccine development and cellular immunity studies. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a critical role in presenting viral peptides, such as the renowned HIV Gag-derived epitope SLYNTVATL, to CD8+ T cells, which are vital for effective immune responses. The interaction between HLA-A*02:01 and the HIV Gag peptide is crucial for understanding how the immune system recognizes and reacts to HIV infections. By engineering a monomeric form of this complex, researchers aim to facilitate structural and functional studies that can elucidate the mechanisms of T cell recognition and activation. This approach not only aids in dissecting the intricate pathways of HIV pathogenesis but also paves the way for designing effective immunotherapies and vaccines that harness the body's immune response against HIV. Furthermore, employing such recombinant proteins can contribute to the development of tools for monitoring immune responses in vaccine trials, ultimately striving to achieve durable viral control in HIV-infected individuals.
